title: Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi.
abstract: OBJECTIVE
  To evaluate the effectiveness of sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi.
  
  
  METHODS
  Prospective open label extension study.
  
  
  METHODS
  Urology clinics at the Nairobi Hospital, Kenyatta National Hospital and the author's private clinic in Hurlingham, Nairobi.
  
  
  METHODS
  Two hundred and nineteen adult male patients with erectile dysfunction.
  
  
  RESULTS
  The age range was 33-80 years with a mean of 62.5 years and a peak incidence in the 60-69 year age group. One hundred and nineteen patients (54.34%) had organic causes, 85 patients (38.81%) had psychogenic causes and 15 patients had mixed causes. Two hundred patients (91.32%) had improved sexual function after treatment with viagra. This improvement was sustained during the study period of sixteen weeks and included improved erectile and orgasmic functions and overall sexual satisfaction. One hundred and fifty seven of these patients responded to therapy with 50 mg of viagra; 40 patients with 25 mg and three patients with 100 mg of therapy. Nineteen patients (8.68%) had no improvement in sexual function after viagra administration. Seven patients (3.2%) had adverse effects which were mild and transient. They included mild headaches in three patients, mild dyspepsia in two patients and facial flushing and nausea and vomiting in one patient, respectively.
  
  
  CONCLUSIONS
  Oral sildenafil (Viagra) is an effective well tolerated and simple treatment for male erectile dysfunction in the majority of cases. The cost of treatment at about ten United States dollars for the 50 mg tablet is prohibitive and may limit its wide use by many deserving patients in this locality.
authors.affiliation: Department of Surgery, College of Health Sciences, University of Nairobi, Kenya.
authors.forename: G A
authors.initials: GA
authors.lastname: Magoha
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016527:Drug Costs; D004415:Dyspepsia / Q000139:chemically induced; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007630:Kenya; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014504:Urban Health
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases